<DOC>
	<DOCNO>NCT00140751</DOCNO>
	<brief_summary>The purpose study compare efficacy tolerance treatment simplification Lopinavir/ritonavir monotherapy versus continuation current treatment HIV-infected patient</brief_summary>
	<brief_title>Comparison Treatment Simplification LPV/r v Current Treatment Continuation HIV-Infected Patients</brief_title>
	<detailed_description>Highly active antiretroviral therapy ( HAART ) make significant impact natural history HIV-1 infection , toxicity complexity therapy limit long-term efficacy , make simpler yet effective HAART regimens highly desirable . Previous attempt 'de-intensify ' protease inhibitor ( PI ) -based therapy discontinue reverse transcriptase inhibitor ( RTI ) achieve viral suppression meet failure , probably plasma level individually administer PI low inhibit viral replication consistently . Low-dose ritonavir substantially enhance lopinavir plasma level , lopinavir/ritonavir ( LPV/r ) effective part combination therapy naive PI-experienced patient . Furthermore , lopinavir know high genetic barrier selection resistance . LPV/r monotherapy could thus right combination potency , favorable pharmacokinetics , high genetic barrier need suppress viral replication prevent selection lopinavir resistance . Preliminary result `` maintenance '' LPV/r monotherapy show interesting result data randomize study need .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Age &gt; = 18 year Confirmed HIV1 seropositivity Antiretroviral treatment stable since 3 month least HIV1 ARN load &lt; 50 copies/mL since 6 month least Signed consent form No history treatment failure ( = viral load &gt; 1000 copies/mL ) include protease inhibitor No opportunistic infection previous 6 month Neutrophils &lt; 750/mm3 Hemoglobin &lt; 8 g/dL Platelets &lt; 60,000/mm3 Creatinin &gt; 150 micromoles/L SGOT &gt; 5 NUL ( Normal Upper Limit ) SGPT &gt; 5 NUL Current IL2 treatment HBV infection treat lamivudine tenofovir Pregnancy feed Enrollment another study compliant KALESOLO Study group assignment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Treatment simplification</keyword>
	<keyword>Lopinavir/ritonavir</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>HIV Seropositivity</keyword>
</DOC>